Rat (pivotal GLP); cynomolgus monkey for biodistribution/excipient studies
“The nonclinical safety program conducted to characterize the toxicity and biodistribution of eladocagene exuparvovec comprised of two studies, a 30-day study, and a 6 month study, both in rats.”
No surrogate; clinical vector in rat; NHP used rAAV2-hAADC and rAAV2-eGFP reporter vector
“The recombinant adeno-associated virus, serotype 2 (rAAV2) vector was identical to that used for eladocagene exuparvovec and this study also evaluated limited toxicological parameters.”